Dr. Adam J. Olszewski
Claim this profileRhode Island Hospital
Studies Mantle Cell Lymphoma
Studies Lymphoma
11 reported clinical trials
25 drugs studied
Area of expertise
1Mantle Cell Lymphoma
t(11;14) positive
CCND1 positive
Stage I
2Lymphoma
CD10 positive
BCL6 positive
CXCL13 positive
Affiliated Hospitals
Clinical Trials Adam J. Olszewski is currently running
Rituximab vs Mosunetuzumab
for Follicular Lymphoma
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Recruiting2 awards Phase 313 criteria
Zanubrutinib
for Mantle Cell Lymphoma
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
Recruiting2 awards Phase 310 criteria
More about Adam J. Olszewski
Clinical Trial Related4 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Adam J. Olszewski has experience with
- Rituximab
- Cyclophosphamide
- Mosunetuzumab
- SGR-1505
- Chemotherapy
- CDX-1140
Breakdown of trials Adam J. Olszewski has run
Mantle Cell Lymphoma
Lymphoma
Non-Hodgkin's Lymphoma
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Adam J. Olszewski specialize in?
Adam J. Olszewski focuses on Mantle Cell Lymphoma and Lymphoma. In particular, much of their work with Mantle Cell Lymphoma has involved t(11;14) positive patients, or patients who are CCND1 positive.
Is Adam J. Olszewski currently recruiting for clinical trials?
Yes, Adam J. Olszewski is currently recruiting for 5 clinical trials in Providence Rhode Island. If you're interested in participating, you should apply.
Are there any treatments that Adam J. Olszewski has studied deeply?
Yes, Adam J. Olszewski has studied treatments such as Rituximab, Cyclophosphamide, Mosunetuzumab.
What is the best way to schedule an appointment with Adam J. Olszewski?
Apply for one of the trials that Adam J. Olszewski is conducting.
What is the office address of Adam J. Olszewski?
The office of Adam J. Olszewski is located at: Rhode Island Hospital, Providence, Rhode Island 02903 United States. This is the address for their practice at the Rhode Island Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.